RT Journal Article
SR Electronic
T1 Novel discoveries and enhanced genomic prediction from modelling genetic risk of cancer age-at-onset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.25.22272955
DO 10.1101/2022.03.25.22272955
A1 Maksimova, Ekaterina S.
A1 Ojavee, Sven E.
A1 Läll, Kristi
A1 Sadler, Marie C.
A1 Mägi, Reedik
A1 Kutalik, Zoltan
A1 Robinson, Matthew R.
YR 2023
UL http://medrxiv.org/content/early/2023/06/06/2022.03.25.22272955.abstract
AB Genome-wide association studies seek to attribute disease risk to DNA regions and facilitate subject-specific prediction and patient stratification. For later-life diseases, inference from case-control studies is hampered by the uncertainty that control group subjects might later be diagnosed. Time-to-event analysis treats controls as right-censored, making no additional assumptions about future disease occurrence and represents a more sound conceptual alternative for more accurate inference. Here, using data on 11 common cancers from the UK and Estonian Biobank studies, we provide empirical evidence that discovery and genomic prediction are greatly improved by analysing age-at-diagnosis, compared to a case-control model of association. We replicate previous findings from large-scale case-control studies and find an additional 7 previously unreported independent genomic regions, out of which 3 replicated in independent data. Our novel discoveries provide new insights into underlying cancer pathways, and our model yields a better understanding of the polygenicity and genetic architecture of the 11 tumours. We find that heritable germline genetic variation plays a vital role in cancer occurrence, with risk attributable to many thousands of underlying genomic regions. Finally, we show that Bayesian modelling strategies utilising time-to-event data increase prediction accuracy by an average of 20% compared to a recent summary statistic approach (LDpred-funct). As sample sizes increase, incorporating time-to-event data should be commonplace, improving case-control studies by using richer information about the disease process.Competing Interest StatementMRR receives research funding from Boehringer Ingelheim. SEO is an employee of MSD at the time of the submission, contribution to the research occurred during the affiliation at the University of Lausanne.Funding StatementThis study was funded by SNSF Eccellenza Grant to MRR (PCEGP3-181181) and by core funding from the Institute of Science and Technology Austria and the University of Lausanne. KL and RM were supported by the Estonian Research Council grant PRG687.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Estonian Committee on Bioethics and Human Research gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.